Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

  • Post author:
  • Post category:uncategorized

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.